

Taotao Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5487150/publications.pdf>

Version: 2024-02-01

14
papers

350
citations

1163117

8
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

436
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 436-442.	2.5	96
2	Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 463-470.	3.0	75
3	Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. <i>International Journal of Infectious Diseases</i> , 2014, 18, 62-67.	3.3	49
4	Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study. <i>International Journal of Infectious Diseases</i> , 2018, 72, 49-54.	3.3	34
5	Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections. <i>Pharmacotherapy</i> , 2015, 35, 797-804.	2.6	23
6	Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. <i>International Journal of Infectious Diseases</i> , 2014, 22, 35-40.	3.3	22
7	Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 239-246.	0.6	14
8	Methylenetetrahydrofolate reductase gene polymorphisms contribute to acute myeloid leukemia and chronic myeloid leukemia susceptibilities: Evidence from meta-analyses. <i>Cancer Epidemiology</i> , 2014, 38, 471-478.	1.9	9
9	Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis. <i>Pharmacotherapy</i> , 2021, 41, 172-183.	2.6	8
10	Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy. <i>Pharmaceutics</i> , 2022, 14, 842.	4.5	6
11	Therapeutic Drug Monitoring and Nephrotoxicity of Teicoplanin Therapy in Chinese Children: A Retrospective Study. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4105-4113.	2.7	5
12	Modeling and forecasting <i>Acinetobacter baumannii</i> resistance to set appropriate use of cefoperazone-sulbactam: Results from trend analysis of antimicrobial consumption and development of resistance in a tertiary care hospital. <i>American Journal of Infection Control</i> , 2015, 43, 861-864.	2.3	4
13	Choosing Optimal Antibiotics for the Treatment of Patients Infected With Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 656790.	3.5	3
14	Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1548-1555.	1.5	2